Acurx (ACXP) director Carl Sailer awarded 2,150 stock options at $2.36

Rhea-AI Filing Summary

Acurx Pharmaceuticals director Carl Sailer received a stock option grant tied to his service on the company’s board. The award covers 2,150 options for Common Stock at an exercise price of $2.36 per share.

The options were granted as part of Acurx’s Director Compensation Policy and will fully vest on April 20, 2027. Following this award, Sailer holds stock options for 2,150 underlying shares, which are scheduled to expire on April 20, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sailer Carl

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	2,150	$0.00	--

Holdings After Transaction: Stock Option — 2,150 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 2,150 options Exercise price: $2.36 per share Options after transaction: 2,150 options +3 more

6 metrics

Stock options granted 2,150 options Grant related to service on board of directors

Exercise price $2.36 per share Conversion or exercise price for the stock options

Options after transaction 2,150 options Total derivative securities following the grant

Vesting date April 20, 2027 Date when options vest under Director Compensation Policy

Expiration date April 20, 2036 Option expiration if not exercised

Transaction code A (grant/award acquisition) SEC Form 4 transaction code description

Key Terms

Stock Option, Director Compensation Policy, vest, Common Stock

4 terms

Stock Option financial

"security_title: "Stock Option" tied to Common Stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Director Compensation Policy financial

"granted pursuant to the Issuer's Director Compensation Policy"

vest financial

"The shares subject to the options shall vest on April 20, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Common Stock financial

"underlying_security_title: "Common Stock" for the option"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sailer Carl

(Last) (First) (Middle)

C/O ACURX PHARMACEUTICALS, INC.,

259 LIBERTY AVENUE

(Street)

STATEN ISLAND NEW YORK 10305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acurx Pharmaceuticals, Inc. [ ACXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.36	04/20/2026		A		2,150(1)		04/20/2027	04/20/2036	Common Stock	2,150	$0	2,150	D

Explanation of Responses:

1. This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

	/s/ Kostantinos Skordalos, Power of Attorney For: Carl V. Sailer	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Acurx Pharmaceuticals (ACXP) director Carl Sailer report on this Form 4?

Carl Sailer reported receiving a stock option grant for 2,150 shares of Acurx Pharmaceuticals Common Stock. The grant is compensation for his board service and gives him the right to buy shares at a fixed exercise price.

What are the key terms of Carl Sailer’s Acurx (ACXP) stock option grant?

The grant covers 2,150 stock options with an exercise price of $2.36 per share. These options relate to Acurx Common Stock, were awarded for board service, and will expire on April 20, 2036 if not exercised.

When do Carl Sailer’s Acurx (ACXP) stock options vest and become exercisable?

The filing states the 2,150 stock options vest on April 20, 2027. Vesting means they become exercisable on that date, consistent with Acurx’s Director Compensation Policy described in the Form 4 footnote.

How many Acurx (ACXP) stock options does Carl Sailer hold after this transaction?

After this grant, Carl Sailer holds 2,150 stock options linked to Acurx Common Stock, according to the Form 4. This total reflects the options covered by the reported award following the transaction.

Is Carl Sailer’s Acurx (ACXP) stock option grant an open-market purchase or compensation?

The Form 4 shows the transaction as a grant or award acquisition with a price of $0.00 per option. A footnote explains it is compensation under the Director Compensation Policy, not an open-market share purchase.